Breaking News Instant updates and real-time market news.

MSFT

Microsoft

$272.20 /

-7.21 (-2.58%)

17:37
03/20/23
03/20
17:37
03/20/23
17:37

OpenAI-powered app from Nuance will instantly transcribe patient notes

Nuance Communications, a Microsoft Company, announced Dragon Ambient eXperience or DAX Express, a workflow-integrated, fully automated clinical documentation application that is the first to combine proven conversational and ambient AI with OpenAI's newest and most capable model, GPT-4. Extending the proven Dragon Medical portfolio of solutions and building on the market-leading DAX ambient solution launched in 2020, DAX Express is the next milestone in Nuance's long-standing mission to reduce administrative burden and empower clinicians to spend more time taking care of patients and less time on paperwork. .. Using a unique combination of conversational, ambient, and generative AI, DAX Express automatically and securely creates draft clinical notes in seconds for immediate clinical review and completion after each patient visit in the exam room or via telehealth patient conversations. Clinicians will benefit from the seamless capabilities of Dragon Medical One, DAX, and DAX Express, which are tightly integrated into the electronic medical record, beginning from pre-visit through post-encounter, reducing cognitive burdens and helping increase the joy of practicing medicine. "Nuance and Microsoft came together with the goal of helping to digitally transform healthcare, and we are marking the next step forward in the ongoing evolution of AI-powered solutions for overburdened care providers," said Mark Benjamin, CEO of Nuance. "We've taken the power and advanced reasoning capabilities of GPT-4 and integrated it into our proven outcomes-focused AI technologies in a tested and responsible way. Our state-of-the-art blend of conversational, ambient, and generative AI will accelerate the advancement of the care delivery ecosystem beyond what Nuance or Microsoft could have achieved separately - expanding our comprehensive portfolio of solutions that fulfill our vision to improve care quality and support enhanced outcomes for generations to come." Reference Link

  • 22

    Mar

OTHER BREAKING NEWS FROM THE FLY

Periodicals
Twitter loses another senior executive in charge of content, safety, WSJ says » 17:46
06/03/23
06/03
17:46
06/03/23
17:46
TWTR

Twitter

$53.71 /

+ (+0.00%)

A second senior executive…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:46

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$53.71 /

+ (+0.00%)

TWTR Twitter
$53.71 /

+ (+0.00%)

05/12/23 Wedbush
New Twitter CEO positive for Tesla shares, says Wedbush
02/03/23 Morgan Stanley
Sprout, Sprinklr pacts minimize impact of Twitter decision, says Morgan Stanley
12/19/22 Wedbush
End of Twitter CEO reign would be 'major positive' for Tesla, says Wedbush
11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
TWTR Twitter
$53.71 /

+ (+0.00%)

TWTR Twitter
$53.71 /

+ (+0.00%)

Hot Stocks
Janssen Pharmaceuticals announces updated data from Phase 2 TRiMM-2 study » 17:39
06/03/23
06/03
17:39
06/03/23
17:39
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Janssen presents analysis of infections, parameters in Monumen-TAL1 study » 17:39
06/03/23
06/03
17:39
06/03/23
17:39
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study » 17:39
06/03/23
06/03
17:39
06/03/23
17:39
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Replimune Group announces 3 trial-in-progress abstracts at ASCO » 17:26
06/03/23
06/03
17:26
06/03/23
17:26
REPL

Replimune Group

$19.00 /

+0.55 (+2.98%)

Additional Abstracts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

04/17/23 Piper Sandler
Replimune Group assumed with an Overweight at Piper Sandler
02/10/23 H.C. Wainwright
Replimune Group price target raised to $50 from $48 at H.C. Wainwright
01/04/23 EF Hutton
Replimune Group initiated with a Buy at EF Hutton
01/02/23 Barclays
Barclays views GSK acquisition interest as positive for oncology stocks
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

  • 09
    Dec
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

Hot Stocks
Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO » 17:26
06/03/23
06/03
17:26
06/03/23
17:26
REPL

Replimune Group

$19.00 /

+0.55 (+2.98%)

, BMY

Bristol-Myers

$65.66 /

+0.98 (+1.52%)

Replimune Group (REPL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

04/17/23 Piper Sandler
Replimune Group assumed with an Overweight at Piper Sandler
02/10/23 H.C. Wainwright
Replimune Group price target raised to $50 from $48 at H.C. Wainwright
01/04/23 EF Hutton
Replimune Group initiated with a Buy at EF Hutton
01/02/23 Barclays
Barclays views GSK acquisition interest as positive for oncology stocks
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

05/01/23 Barclays
Bristol-Myers price target lowered to $65 from $66 at Barclays
04/28/23 Credit Suisse
Bristol-Myers price target lowered to $72 from $78 at Credit Suisse
04/21/23 BofA
Bristol-Myers price target raised to $85 from $82 at BofA
04/20/23 H.C. Wainwright
Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

  • 09
    Dec
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

Hot Stocks
Replimune presents RP1 data from IGNYTE trial at ASCO » 17:26
06/03/23
06/03
17:26
06/03/23
17:26
REPL

Replimune Group

$19.00 /

+0.55 (+2.98%)

, BMY

Bristol-Myers

$65.66 /

+0.98 (+1.52%)

Replimune (REPL)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26

Get Free Trial

ShowHide Related Items >><<
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

04/17/23 Piper Sandler
Replimune Group assumed with an Overweight at Piper Sandler
02/10/23 H.C. Wainwright
Replimune Group price target raised to $50 from $48 at H.C. Wainwright
01/04/23 EF Hutton
Replimune Group initiated with a Buy at EF Hutton
01/02/23 Barclays
Barclays views GSK acquisition interest as positive for oncology stocks
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

05/01/23 Barclays
Bristol-Myers price target lowered to $65 from $66 at Barclays
04/28/23 Credit Suisse
Bristol-Myers price target lowered to $72 from $78 at Credit Suisse
04/21/23 BofA
Bristol-Myers price target raised to $85 from $82 at BofA
04/20/23 H.C. Wainwright
Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

  • 09
    Dec
BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

REPL Replimune Group
$19.00 /

+0.55 (+2.98%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

BMY Bristol-Myers
$65.66 /

+0.98 (+1.52%)

Conference/Events
BTIG healthcare analysts to hold a reception » 17:25
06/03/23
06/03
17:25
06/03/23
17:25

Healthcare Analysts hold…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:25

Get Free Trial

Hot Stocks
Janssen announces results from Phase 1b RedirecTT-1 study » 17:18
06/03/23
06/03
17:18
06/03/23
17:18
JNJ

Johnson & Johnson

$156.98 /

+2.44 (+1.58%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:18

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

05/30/23 RBC Capital
Kenvue initiated with an Outperform at RBC Capital
05/30/23 Citi
Johnson & Johnson resumed with a Buy at Citi
05/30/23 JPMorgan
JPMorgan starts Kenvue with Overweight on 'resilient growth'
05/30/23 Goldman Sachs
Kenvue initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

JNJ Johnson & Johnson
$156.98 /

+2.44 (+1.58%)

Hot Stocks
Evaxion's trial of EVX-01 met its primary endpoints of safety, tolerability » 17:09
06/03/23
06/03
17:09
06/03/23
17:09
EVAX

Evaxion Biotech

$1.48 /

+ (+0.00%)

Evaxion Biotech presented…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:09

Get Free Trial

ShowHide Related Items >><<
EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

03/31/23 Lake Street
Evaxion Biotech price target lowered to $7 from $18 at Lake Street
11/17/22 Oppenheimer
Evaxion Biotech price target lowered to $11 from $16 at Oppenheimer
07/18/22 Oppenheimer
Evaxion Biotech assumed with an Outperform at Oppenheimer
EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

EVAX Evaxion Biotech
$1.48 /

+ (+0.00%)

Hot Stocks
Gracell presents long-term follow up data from study evaluating GC012F » 17:07
06/03/23
06/03
17:07
06/03/23
17:07
GRCL

Gracell

$3.05 /

+0.09 (+3.04%)

Gracell Biotechnologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:07

Get Free Trial

ShowHide Related Items >><<
GRCL Gracell
$3.05 /

+0.09 (+3.04%)

GRCL Gracell
$3.05 /

+0.09 (+3.04%)

03/27/23 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
12/08/22 H.C. Wainwright
Gracell initiated with a Buy at H.C. Wainwright
09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
GRCL Gracell
$3.05 /

+0.09 (+3.04%)

Hot Stocks
Sutro Biopharma announces results from Phase 1 dose-expansion study of luvelta » 17:02
06/03/23
06/03
17:02
06/03/23
17:02
STRO

Sutro Biopharma

$4.71 /

+0.255 (+5.72%)

Sutro Biopharma announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:02

Get Free Trial

ShowHide Related Items >><<
STRO Sutro Biopharma
$4.71 /

+0.255 (+5.72%)

STRO Sutro Biopharma
$4.71 /

+0.255 (+5.72%)

04/03/23 JMP Securities
Sutro Biopharma price target lowered to $17 from $20 at JMP Securities
03/31/23 H.C. Wainwright
Sutro Biopharma price target lowered to $16 from $20 at H.C. Wainwright
03/20/23 Wells Fargo
Sutro transferred with Equal Weight from Overweight at Wells Fargo
01/13/23 Truist
Sutro Biopharma price target raised to $25 from $21 at Truist
STRO Sutro Biopharma
$4.71 /

+0.255 (+5.72%)

Hot Stocks
Equitrans Midstream's Mountain Valley Pipeline to proceed » 16:58
06/03/23
06/03
16:58
06/03/23
16:58
ETRN

Equitrans Midstream

$9.08 /

+0.24 (+2.71%)

On June 3, 2023, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:58

Get Free Trial

ShowHide Related Items >><<
ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

06/01/23 Wolfe Research
Equitrans Midstream upgraded to Outperform from Peer Perform at Wolfe Research
05/30/23 RBC Capital
Equitrans Midstream upgraded to Outperform from Sector Perform at RBC Capital
04/21/23 Raymond James
Equitrans Midstream initiated with a Market Perform at Raymond James
04/10/23 Barclays
Equitrans Midstream price target lowered to $6 from $8 at Barclays
ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

ETRN Equitrans Midstream
$9.08 /

+0.24 (+2.71%)

Hot Stocks
Cogent Biosciences announces data from ongoing Phase 3 PEAK trial » 16:56
06/03/23
06/03
16:56
06/03/23
16:56
COGT

Cogent Biosciences

$12.97 /

+0.245 (+1.93%)

Cogent Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:56

Get Free Trial

ShowHide Related Items >><<
COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

04/27/23 Baird
Cogent Biosciences initiated with Outperform, $20 target at Baird
04/27/23 Baird
Cogent Biosciences initiated with an Outperform at Baird
04/17/23 Wedbush
Wedbush remains bullish on Cogent, says APEX Part 2 likely to succeed
03/27/23 H.C. Wainwright
Cogent Biosciences assumed with a Buy at H.C. Wainwright
COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

  • 14
    Jun
COGT Cogent Biosciences
$12.97 /

+0.245 (+1.93%)

Hot Stocks
Gilead, Arcus announce updated results from interim analysis of ARC-7 study » 16:53
06/03/23
06/03
16:53
06/03/23
16:53
GILD

Gilead

$77.88 /

+1.665 (+2.18%)

, RCUS

Arcus Biosciences

$21.00 /

+0.71 (+3.50%)

Gilead Science (GILD) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:53

Get Free Trial

ShowHide Related Items >><<
RCUS Arcus Biosciences
$21.00 /

+0.71 (+3.50%)

GILD Gilead
$77.88 /

+1.665 (+2.18%)

GILD Gilead
$77.88 /

+1.665 (+2.18%)

06/02/23 Argus
Gilead continues to make regulatory progress, says Argus
05/16/23 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
04/28/23 Piper Sandler
Gilead assumed with an Overweight at Piper Sandler
04/12/23 Morgan Stanley
Gilead price target raised to $85 from $81 at Morgan Stanley
RCUS Arcus Biosciences
$21.00 /

+0.71 (+3.50%)

05/31/23 Barclays
Barclays reveals two small cap ideas into ASCO conference
05/26/23 Citi
Arcus Biosciences price target raised to $41 from $40 at Citi
03/09/23 Citi
Arcus Biosciences price target lowered to $40 from $42 at Citi
12/21/22 Citi
Arcus Biosciences selloff a buying opportunity, says Citi
RCUS Arcus Biosciences
$21.00 /

+0.71 (+3.50%)

GILD Gilead
$77.88 /

+1.665 (+2.18%)

RCUS Arcus Biosciences
$21.00 /

+0.71 (+3.50%)

GILD Gilead
$77.88 /

+1.665 (+2.18%)

GILD Gilead
$77.88 /

+1.665 (+2.18%)

Conference/Events
Alamo Group participates in a conference call with DA Davidson » 14:27
06/03/23
06/03
14:27
06/03/23
14:27
ALG

Alamo Group

$178.29 /

+11.4 (+6.83%)

Analyst Shlisky holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 14:27

Get Free Trial

ShowHide Related Items >><<
ALG Alamo Group
$178.29 /

+11.4 (+6.83%)

ALG Alamo Group
$178.29 /

+11.4 (+6.83%)

03/16/23 DA Davidson
Alamo Group upgraded to Buy from Neutral at DA Davidson
02/27/23 DA Davidson
Alamo Group price target raised to $173 from $156 at DA Davidson
11/07/22 DA Davidson
Alamo Group price target raised to $156 from $136 at DA Davidson
10/19/22 EF Hutton
Alamo Group initiated with a Buy at EF Hutton
ALG Alamo Group
$178.29 /

+11.4 (+6.83%)

Conference/Events
Alamo Group management to meet virtually with DA Davidson » 14:04
06/03/23
06/03
14:04
06/03/23
14:04
ALG

Alamo Group

$178.29 /

+11.4 (+6.83%)

Analyst Shlisky holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 14:04

Get Free Trial

ShowHide Related Items >><<
ALG Alamo Group
$178.29 /

+11.4 (+6.83%)

ALG Alamo Group
$178.29 /

+11.4 (+6.83%)

03/16/23 DA Davidson
Alamo Group upgraded to Buy from Neutral at DA Davidson
02/27/23 DA Davidson
Alamo Group price target raised to $173 from $156 at DA Davidson
11/07/22 DA Davidson
Alamo Group price target raised to $156 from $136 at DA Davidson
10/19/22 EF Hutton
Alamo Group initiated with a Buy at EF Hutton
ALG Alamo Group
$178.29 /

+11.4 (+6.83%)

Conference/Events
Peoples Bancorp management to meet virtually with DA Davidson » 13:59
06/03/23
06/03
13:59
06/03/23
13:59
PEBO

Peoples Bancorp

$27.74 /

+1.72 (+6.61%)

Analyst Navas holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:59

Get Free Trial

ShowHide Related Items >><<
PEBO Peoples Bancorp
$27.74 /

+1.72 (+6.61%)

PEBO Peoples Bancorp
$27.74 /

+1.72 (+6.61%)

04/13/23 Janney Montgomery Scott
Peoples Bancorp initiated with a Neutral at Janney Montgomery Scott
02/27/23 Raymond James
Limestone Bancorp downgraded to Market Perform from Outperform at Raymond James
10/26/22 Hovde Group
Peoples Bancorp downgraded to Market Perform from Outperform at Hovde Group
08/03/22 B. Riley
Peoples Bancorp price target raised to $32 from $28 at B. Riley
PEBO Peoples Bancorp
$27.74 /

+1.72 (+6.61%)

Hot Stocks
NewAmsterdam's ROSE2 trial on obicetrapib met primary, secondary endpoints » 13:14
06/03/23
06/03
13:14
06/03/23
13:14
NAMS

NewAmsterdam

$13.78 /

+0.025 (+0.18%)

NewAmsterdam Pharma…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:14

Get Free Trial

ShowHide Related Items >><<
NAMS NewAmsterdam
$13.78 /

+0.025 (+0.18%)

NAMS NewAmsterdam
$13.78 /

+0.025 (+0.18%)

01/06/23 Credit Suisse
NewAmsterdam initiated with an Outperform at Credit Suisse
12/20/22 SVB Securities
NewAmsterdam initiated with an Outperform at SVB Securities
12/19/22 William Blair
William Blair starts NewAmsterdam at Outperform on obicetrapib confidence
12/19/22 William Blair
NewAmsterdam initiated with an Outperform at William Blair
NAMS NewAmsterdam
$13.78 /

+0.025 (+0.18%)

Hot Stocks
Precigen announces Phase 1 data of OTS PRGN-2009 AdenoVerse » 13:09
06/03/23
06/03
13:09
06/03/23
13:09
PGEN

Precigen

$1.30 /

+ (+0.00%)

Precigen presented…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:09

Get Free Trial

ShowHide Related Items >><<
PGEN Precigen
$1.30 /

+ (+0.00%)

PGEN Precigen
$1.30 /

+ (+0.00%)

05/23/23 JPMorgan
Precigen initiated with a Neutral at JPMorgan
01/30/23 Cantor Fitzgerald
Precigen price target raised to $10 from $7 at Cantor Fitzgerald
12/28/22 Cantor Fitzgerald
Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
PGEN Precigen
$1.30 /

+ (+0.00%)

  • 25
    Jan
PGEN Precigen
$1.30 /

+ (+0.00%)

PGEN Precigen
$1.30 /

+ (+0.00%)

Hot Stocks
Elevation Oncology, CSPC announces initial clinical data for SYSA1801 » 13:02
06/03/23
06/03
13:02
06/03/23
13:02
ELEV

Elevation Oncology

$3.54 /

-0.46 (-11.50%)

, CSPCY

CSPC

$3.43 /

+0.02 (+0.59%)

Elevation Oncology (ELEV)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:02

Get Free Trial

ShowHide Related Items >><<
ELEV Elevation Oncology
$3.54 /

-0.46 (-11.50%)

ELEV Elevation Oncology
$3.54 /

-0.46 (-11.50%)

05/30/23 SVB Securities
SVB upgrades Elevation Oncology to Outperform on Claudin18.2 ADC SYSA180 data
05/30/23 SVB Securities
Elevation Oncology upgraded to Outperform from Market Perform at SVB Securities
11/10/22 JPMorgan
Elevation downgraded to Underweight on more difficult path at JPMorgan
11/10/22 JPMorgan
Elevation Oncology downgraded to Underweight from Neutral at JPMorgan
CSPCY CSPC
$3.43 /

+0.02 (+0.59%)

08/02/22 Deutsche Bank
CSPC initiated with a Buy at Deutsche Bank
ELEV Elevation Oncology
$3.54 /

-0.46 (-11.50%)

Hot Stocks
Blueprint Medicines announces data from its VELA trial of BLU-222 » 12:59
06/03/23
06/03
12:59
06/03/23
12:59
BPMC

Blueprint Medicines

$58.22 /

+1.39 (+2.45%)

Blueprint Medicines…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:59

Get Free Trial

ShowHide Related Items >><<
BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

05/23/23 Guggenheim
Blueprint Medicines price target raised to $82 from $78 at Guggenheim
05/23/23 H.C. Wainwright
Blueprint Medicines price target raised to $85 from $75 at H.C. Wainwright
05/23/23 Barclays
Blueprint Medicines price target raised to $46 from $44 at Barclays
05/05/23 H.C. Wainwright
Blueprint Medicines price target raised to $75 from $70 at H.C. Wainwright
BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

Hot Stocks
Blueprint Medicines announces results from its EGFR Programs » 12:59
06/03/23
06/03
12:59
06/03/23
12:59
BPMC

Blueprint Medicines

$58.22 /

+1.39 (+2.45%)

Blueprint Medicines…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:59

Get Free Trial

ShowHide Related Items >><<
BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

05/23/23 Guggenheim
Blueprint Medicines price target raised to $82 from $78 at Guggenheim
05/23/23 H.C. Wainwright
Blueprint Medicines price target raised to $85 from $75 at H.C. Wainwright
05/23/23 Barclays
Blueprint Medicines price target raised to $46 from $44 at Barclays
05/05/23 H.C. Wainwright
Blueprint Medicines price target raised to $75 from $70 at H.C. Wainwright
BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

BPMC Blueprint Medicines
$58.22 /

+1.39 (+2.45%)

Hot Stocks
Merck announces results from Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA » 12:50
06/03/23
06/03
12:50
06/03/23
12:50
MRK

Merck

$112.52 /

+1.56 (+1.41%)

Merck, known as MSD…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:50

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$112.52 /

+1.56 (+1.41%)

MRK Merck
$112.52 /

+1.56 (+1.41%)

05/10/23 Jefferies
Prometheus downgraded to Hold from Buy at Jefferies
05/01/23 Barclays
Merck price target raised to $130 from $128 at Barclays
04/18/23 Wells Fargo
Prometheus downgraded to Equal Weight from Overweight at Wells Fargo
04/18/23 RBC Capital
Prometheus downgraded to Sector Perform from Outperform at RBC Capital
MRK Merck
$112.52 /

+1.56 (+1.41%)

MRK Merck
$112.52 /

+1.56 (+1.41%)

MRK Merck
$112.52 /

+1.56 (+1.41%)

MRK Merck
$112.52 /

+1.56 (+1.41%)

Hot Stocks
Allogene Therapeutics presents updated ALLO-501/501A Phase 1 data » 12:45
06/03/23
06/03
12:45
06/03/23
12:45
ALLO

Allogene Therapeutics

$5.60 /

+0.28 (+5.26%)

Allogene Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:45

Get Free Trial

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$5.60 /

+0.28 (+5.26%)

ALLO Allogene Therapeutics
$5.60 /

+0.28 (+5.26%)

05/05/23 JMP Securities
Allogene Therapeutics price target lowered to $15 from $19 at JMP Securities
05/04/23 Stifel
Allogene Therapeutics price target lowered to $7.50 from $8.00 at Stifel
04/04/23 H.C. Wainwright
Allogene Therapeutics price target lowered to $23 from $29 at H.C. Wainwright
03/21/23 Bernstein
Allogene Therapeutics initiated with a Market Perform at Bernstein
ALLO Allogene Therapeutics
$5.60 /

+0.28 (+5.26%)

ALLO Allogene Therapeutics
$5.60 /

+0.28 (+5.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.